Physician profile
Michael B Levandowski
NPI 1023275955
$3,926.28
in general payments reported to CMS, 2019-2025
29 companies · $1,665 in 2025
The $1,665 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $147 · 2022: $409 · 2023: $768 · 2024: $938 · 2025: $1,665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,370.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $850.55 | 2021-2025 | Grafix Pl, Oasis, Collagenase Santyl |
| Organogenesis INC. | $626.45 | 2021-2025 | Affinity, Cygnus Dual, Puraply |
| Paratek Pharmaceuticals, INC. | $496.32 | 2022-2025 | Nuzyra, Xhance |
| Novo Nordisk INC | $310.69 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $231.24 | 2023-2025 | Caplyta |
| Convatec INC. | $178.16 | 2024-2025 | |
| Lilly USA, LLC | $158.53 | 2023-2025 | Mounjaro |
| Progenacare Global, LLC | $117.73 | 2023 | |
| Glaxosmithkline, LLC. | $114.32 | 2023-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Otsuka America Pharmaceutical, INC. | $95.32 | 2025 | Rexulti |
| Verona Pharma, INC. | $78.69 | 2025 | Ohtuvayre |
| Exact Sciences Corporation | $78.65 | 2023-2024 | Cologuard Collection Kit |
| Vanda Pharmaceuticals INC. | $78.00 | 2025 | Fanapt |
| Alkermes, INC. | $65.41 | 2025 | Lybalvi |
| Phathom Pharmaceuticals, INC. | $64.95 | 2024-2025 | Voquezna |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $45.31 | 2024-2025 | Austedo Xr, Austedo Xr |
| Axsome Therapeutics, INC. | $44.74 | 2024-2025 | Auvelity |
| Boston Scientific Corporation | $44.03 | 2023 | Varithena Administration Pack |
| Tactile Systems Technology INC | $37.19 | 2025 | Flexitouch Plus, Nimbl |
| Hydrofera LLC | $31.57 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.47 | 2022 | |
| Urgo Medical North America, LLC | $29.92 | 2025 | Urgok2 |
| Cordis US Corp. | $22.38 | 2025 | Mynx Control Venous |
| Bioventus LLC | $18.88 | 2022 | |
| Lundbeck LLC | $18.61 | 2024 | Rexulti |
| Alk-Abello, INC | $16.64 | 2022 | |
| Abbvie INC. | $15.25 | 2025 | |
| Janssen Pharmaceuticals, INC | $13.62 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $11.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Levandowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.